Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats

Journal of Biomedical Research

Volumn 26, Issue 3, 2012, Pages 200-210

  Sharma, Ashish Kumar ^a   Sharma, Akash ^a   Kumari, Rita ^a   Kishore, Kunal ^a   Sharma, Divya ^a   Srinivasan, Bharthu Parthsarthi ^b   Sharma, Ashok ^a   Singh, Santosh Kumar ^a   Gaur, Samir ^a   Jatav, Vijay Singh ^a   Sharma, Prashant ^a   Srivastava, Varnika ^a   Joshi, Sneha ^a   Joshi, Megha ^a   Dhakad, Prashant Kumar ^a   Kanawat, Davender Singh ^a   Mishra, Akanksha ^a   Sharma, Anil ^a   Singh, Dharmendra ^a   Singh, Ravinder Pal ^a   Chawda, Himmat Singh ^a   Singh, Rambir ^a   Raikwar, Sachin Kumar ^a   Kurmi, Muneem Kumar ^a   Khatri, Pankaj ^a   Agarwal, Ashutosh ^b   Munajjam, Arshee ^a,c   more..

^a SURESH GYAN VIHAR UNIVERSITY   (India)

^b DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

^c RIICO Industrial Area ^*  (India)

Author keywords

Amitriptyline; Diabetic neuropathy; Glimipiride; Metformin; Nicotinamide streptozotocin; Pioglitazone; Sitagliptin

Indexed keywords

AMITRIPTYLINE; GLIMEPIRIDE; METFORMIN; NICOTINAMIDE; PIOGLITAZONE; SITAGLIPTIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFECT; GLYCEMIC CONTROL; GRIP STRENGTH; NERVE CELL DEGENERATION; NOCICEPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RAT; TISSUE REGENERATION; TREATMENT RESPONSE;

EID: 84862165743     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.26.20110054     Document Type: Article

References (30)

1. Harris MI, Robbins DC Prevalence of adult-onset IDDM in the US population. Diabetes Care 1994, 17:1337-1340.
2. Landin-Olsson M, Nilsson KO, Lernmark A, Sundkvist G Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabeto-logia 1990, 33:561-568.
3. Apfel SC Introduction to diabetic neuropathy. Am J Med 1999, 107:1S.
4. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents. Regul Pept 2005, 128:159-165.
5. U.S.Food and Drug Administration FDA Approves New Treatment for Diabetes Press release. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01492.html.
6. Dipeptidyl peptidase-4 inhibitors ('gliptins') for type 2 diabetes mellitus. NPS RADAR http://www.nps.org.au/health_professionals/publications/npsradar/2008/august__2008/gliptins.
7. Pari L, Murugan P Changes in glycoprotein components in streptozotocin-nicotinamide induced type 2 diabetes: influence of tetrahydrocurcumin from Curcuma longa. Plant Foods Human Nutr 2007, 62:25-29.
8. Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, et al. Experimental NIDDM: develop-ment of a new model in adult rats administered strepto-zotocin and nicotinamide. Diabetes 1998, 47:224-229.
9. Filho O, Fazan V Streptozotocin induced diabetes as a model of phrenic nerve neuropathy in rats. J Neurosci Methods 2006, 151:131-138.
10. Sharma AK, Srinivasan BP Triple verses glimepiride plus metformin therapy on cardiovascular risk biomark-ers and diabetic cardiomyopathy in insulin resistance type 2 diadetes mellitus rats. Eur J Pharm Sci 2009, 38:433-444.
11. Muller G, Herling AW Anti-diabetic activity. Drug Discovery and Evaluation, Phar-macological Assays 2002, 948-1052. Heidelberg Sprinder-Veriag, Berlin. 2nd edition. G.H. Vogel (Ed.).
12. Woolfe G, MacDonald AD The evaluation of the an-algesic action of pethidine hydrochloride (Demerol). J Pharmacol Exp Ther 1944, 80:300-307.
13. Dorey, Draves. Quantitative analysis laboratory: a new approach funded by the National Science Foundation. University of Central Arkansas, Department of Chemis-try, Conway, AR 72035, Update: 5/98.
14. Gershom BE Screening for albuminuria: a case for esti-mation of albumin urine. Clin Chem 1975, 21:1795-1798.
15. Willis WD, Westlund KN, Carlton SM Pain System. The Rat Nervous System 2004, 853-890. Elsevier, Amsterdam. 3rd edition. G. Paxinos (Ed.).
16. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al. Pharmacokinetics and pharmacody-namics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005, 78:675-688.
17. National Prescribing Service Sitagliptin for Type 2 Diabetes http://www.nps.org.au/consumers/publications/medicine_update/issues/sitagliptin.
18. Olansky L Do incretin-based therapies cause acute pan-creatitis?. J Diabetes Sci Technol 2010, 4:228-229.
19. Pro B, Dang NH CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol 2004, 19:1345-1351.
20. Wesley UV, McGroarty M, Homoyouni A Dipeptidyl peptidase inhibits malignant phenotype of prostate can-cer cells by blocking basic fibroblast growth factor sign-aling pathway. Cancer Res 2005, 65:1325-1334.
21. Tattersall RB, Fajans SS Difference between the inherit-ance of classical juvenile-onset and maturity onset dia-betes of young people. Diabetes 1975, 24:44-53.
22. Dussoix P, Vaxillaire M, Iynejian PB, Tiercy JM, Ruiz J, Spinas GA, et al. Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunologi-cal and genetic parameters. Diabetes 1997, 46:622-631.
23. Fajans SS, Bell GI, Polonsky KS Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001, 345:971-980.
24. Boron WF, Boulpaep EL Cellular physiology of skeletal, cardiac and smooth muscle. Medical Physiology: A Cellular and Mo-lecular Approch 2003, 975-995. Saunders/Elesevier, Philadelphia. 2nd edition. W.F. Boron, E.L. Boulpaep (Eds.).
25. Vaghasiya J, Sheth N, Bhalodia Y, Manek R Sitagliptin protects renal ischemia reperfusion induced renal dam-age in diabetes. Regul Pept 2011, 166:48-54.
26. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, et al. Amitriptyline relieves diabetic neu-ropathy pain in patients with normal or depressed mood. Neurology 1987, 37:589-596.
27. Charbonnel B, Karasik A, Liu J, Wu M, Sitagliptin Study 020 Group Efficacy and safety of the dipeptidyl pepti-dase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643.
28. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010, 26:540-549.
29. Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Ra-schia MA, Francini F, et al. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond) 2011, 120:73-80.
30. Marney A, Kunchakarra S, Byrne L, Brown NJ Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010, 56:728-733.